Abstract
T helper 2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, play an important role in allergic immune disorders, such as bronchial asthma. These cytokines regulate diverse biological functions by binding to receptors at the cell surface to activate complex signal transduction pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and the Ras-extracellular signal-regulated kinase (ERK) signaling pathways. The suppressor of cytokine signaling (SOCS) family proteins has been shown to regulate the JAK-STAT pathway, and the Sprouty-related EVH1-domain-containing protein (SPRED) family proteins regulate the Ras-ERK pathway. SOCS3 and SOCS5 are predominantly expressed in Th2 and Th1 cells, respectively, and they reciprocally inhibit the Th1 and Th2 differentiation processes. SOCS3 also has a role in Th3 differentiation. SPRED-1 is expressed in hematopoietic cells, including eosinophils, and negatively controls the eosinophil numbers and functions by modulating IL-5 signaling. Here, we discuss the role of SOCS and SPRED proteins in allergic asthma and explore the potential of these proteins as targets for therapeutic strategies in allergic asthma.
Keywords: MAP kinase, SOCS proteins, Regulatory T Cells, SPRED-1, Asthma
Current Medicinal Chemistry
Title: Role of Endogenous Inhibitors of Cytokine Signaling in Allergic Asthma
Volume: 14 Issue: 2
Author(s): Hiromasa Inoue, Satoru Fukuyama, Koichiro Matsumoto, Masato Kubo and Akihiko Yoshimura
Affiliation:
Keywords: MAP kinase, SOCS proteins, Regulatory T Cells, SPRED-1, Asthma
Abstract: T helper 2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, play an important role in allergic immune disorders, such as bronchial asthma. These cytokines regulate diverse biological functions by binding to receptors at the cell surface to activate complex signal transduction pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and the Ras-extracellular signal-regulated kinase (ERK) signaling pathways. The suppressor of cytokine signaling (SOCS) family proteins has been shown to regulate the JAK-STAT pathway, and the Sprouty-related EVH1-domain-containing protein (SPRED) family proteins regulate the Ras-ERK pathway. SOCS3 and SOCS5 are predominantly expressed in Th2 and Th1 cells, respectively, and they reciprocally inhibit the Th1 and Th2 differentiation processes. SOCS3 also has a role in Th3 differentiation. SPRED-1 is expressed in hematopoietic cells, including eosinophils, and negatively controls the eosinophil numbers and functions by modulating IL-5 signaling. Here, we discuss the role of SOCS and SPRED proteins in allergic asthma and explore the potential of these proteins as targets for therapeutic strategies in allergic asthma.
Export Options
About this article
Cite this article as:
Inoue Hiromasa, Fukuyama Satoru, Matsumoto Koichiro, Kubo Masato and Yoshimura Akihiko, Role of Endogenous Inhibitors of Cytokine Signaling in Allergic Asthma, Current Medicinal Chemistry 2007; 14 (2) . https://dx.doi.org/10.2174/092986707779313327
DOI https://dx.doi.org/10.2174/092986707779313327 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research
Current Pharmaceutical Design Enzyme Inhibitors
Current Bioactive Compounds Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Determination of the Antiproliferative Activity of New Theobromine Derivatives and Evaluation of Their In Vitro Hepatotoxic Effects
Anti-Cancer Agents in Medicinal Chemistry Syk: A Novel Target for Treatment of Inflammation in Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in PDE4 Inhibitors as Immunoregulators and Anti- Inflammatory Drugs
Current Pharmaceutical Design Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology A Miniaturized Glucocorticoid Receptor Translocation Assay Using Enzymatic Fragment Complementation Evaluated with qHTS
Combinatorial Chemistry & High Throughput Screening Natural Products in Drug Discovery - Concepts and Approaches for Tracking Bioactivity
Current Organic Chemistry Chromatographic Retention Parameters in Medicinal Chemistry and Molecular Pharmacology
Current Medicinal Chemistry Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER<sup>©</sup>) as Monotherapy for Chronic PTSD: A Pilot Study
Adolescent Psychiatry Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design